Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
EQS Group
EQS-News: Formycon AG / Key word(s): Study/Miscellaneous
Formycon starts clinical development program for FYB206, a biosimilar..